Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

Epcoritamab combined with GemOx shows deep, durable responses in transplant-ineligible relapsed/refractory diffuse large ...

Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...